【Internship Program】Market Access Intern (1 year Contract)
3/24 更新
台北市大安區
【Internship Program】Market Access Intern (1 year Contract)

工作待遇

200~300元/時

工作時段

日班|09:00~18:00
工作環境照

工作內容

  • 需求人數

    :1人
  • What does life, change and careers mean to you? This is what it means to us! https://www.youtube.com/watch?v=B3S67JCIR1Y Come to apply if you are ready to make a difference! In our dynamic environment, you will analyze global innovative reimbursement models and policy advocacy programs for diabetes and obesity. This role will sharpen your analytical skills while contributing to significant public affairs initiatives. What will you mainly do | Build and maintain a structured tracker of Primary Care-related cases discussed in the NHI PBRS meetings over the past 5 years, capturing: industry submission price, proposed reimbursement scope/criteria, and final NHIA-approved price and scope. | Analyze end-to-end timelines (submission to listing effective date), identify drivers of longer/shorter timelines (e.g., restriction complexity, scope changes, need for further evidence). | Quantify and summarize differences between: submission price vs. approved reimbursement price, and requested reimbursement scope vs. final scope (indications, criteria, utilization controls). | Extract industry-submitted budget impact assumptions and compare with CDE-estimated budget impact; highlight key sources of discrepancy (eligible population, uptake/penetration, treatment mix, duration, comparators). | Produce a quarterly/monthly insight summary (1–2 pages) and a final slide deck synthesizing 5-year trends in Primary Care reimbursement decisions (coverage tightening/relaxation, pricing outcomes, time-to-access, and budget impact variances). | Support internal stakeholder discussions by translating complex reimbursement decisions into clear implications for Market Access planning and forecasting. We expect you to be | Education: Currently pursuing or recently completed a degree in Public Health, Pharmacy, Health Policy, Epidemiology, Biostatistics, Health Administration, or a related healthcare discipline. | Analytical skills: Strong ability to structure complex information, perform trend analyses, and interpret policy/committee decisions logically. | Data handling: Proficiency in Excel (filters, pivot tables, basic charts) and PowerPoint (clear, structured storytelling). | Communication: Ability to summarize technical/policy content into concise insights for cross-functional stakeholders | Attention to detail: High accuracy in extracting figures, dates, scope wording, and maintaining documentation integrity. Feel like you are the one for this exciting opportunity? Apply now! We commit to an inclusive recruitment process and equality of opportunity for all our job applicants.

工作時段/備註

  • 09:00~18:00

工作地點

  • 地址:敦化南路二段207號10樓
  • 不允許在家工作

公司簡介

台灣諾和諾德藥品股份有限公司

諾和諾德公司是一家先進的生物製藥公司,總部位於丹麥首都哥本哈根。我們在健康照護領域內擁有最廣泛的糖尿病治療產品,其中包括最先進的胰島素產品,我們的目的是推動改變、戰勝糖尿病和其他嚴重的慢性疾病,如肥胖、罕見血液和內分泌疾病,我們的長期抱負是提供負擔得起的糖尿病照顧,讓每個國家的弱勢病患受惠,特別是患有第一型糖尿病的兒童,他們在某些地區因為缺乏照顧和醫療而可能面臨死亡。我們還投注在慢性病的預防上。我們的雄心壯志是到了2045年,可以預防超過1億的人口罹患第二型糖尿病。 Novo Nordisk is a focused healthcare company. With the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems, Novo Nordisk is a world leader in diabetes care. In addition, Novo Nordisk has a leading position in areas such as haemostasis management, growth hormone therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. Our long-term aspiration is to provide affordable diabetes care benefiting vulnerable patients in every country, especially children with type 1 diabetes who may face death in some regions due to lack of care and medical attention. We also invest in the prevention of chronic diseases. Our ambition is to prevent over 100 million people from developing type 2 diabetes by 2045. 諾和諾德公司歷年來在各項企業評比中榮獲無數殊榮。近年的得獎紀錄為: 《2025第二屆 LGBTIQ+台灣同志職場友善指標》認證為台灣同志職場友善企業 《2025天下永續公民獎最佳「外商企業獎」2025 Excellence in Corporate Social Responsibility in Foreign Company Award》 《World’s Best Companies of 2025 》2025全球最佳企業第十五名 《2024 TCSA 台灣企業永續獎- 創意溝通領袖獎項目》 《2024 金商獎優良外商》 《2024 天下人才永續獎外商組》入選 《2024 榮登FORTUNE 世界500強》 《2024 Great Place to Work®「卓越職場認證™」》 《2024 104 最佳雇主品牌獎》 《WORLD'S MOST SUSTAINABLE COMPANIES OF 2024》 《2023 World’s Best Place to Work》由Best place to work 認證為2023年「全球最佳工作場所」第一名 《2023 LGBTIQ+台灣同志職場友善指標》認證為台灣同志職場友善企業 《2023 Healthcare Asia Pharma Award》年度ESG (Environmental, Social & Governance) 計畫優勝 《2022 World's Best Place to Work》 榮獲Best place to work 認證為2022年「全球最佳工作場所」第一名 《2022 BCCT優良企業貢獻獎》榮獲Corporate Social Responsibility 優勝肯定 《2021 Best Place to Work》 榮獲Best Place to Work認證為亞太地區最佳職場第四名 《2021 National Innovation Award》榮獲第18屆國家新創獎國際新創組獎項 《2021台灣金商獎之優良外商》 《環保署綠色辦公響應計畫》獲得環保署綠色辦公夥伴認證 《2019年健康職場認證-台灣諾和諾德》 《製藥企業形象調查》分泌學家評選為最佳企業 《Corporate Knight雜誌》百大永續企業、為製藥業第1名 《Great Place to Work》評為全球最多元職場之一 《全球指數》評為百大永續企業第1名 《R&D Directions雜誌》評為最佳糖尿病製藥產線 《Medical Marketing & Media 月刊》評為年度最佳企業 《Ethisphere商業機構》連續4年被評為百大最具道德企業 《PwC資誠聯合會計師事務所》全球市值百大企業 《Fortune雜誌》全球前25 最值得工作之跨國企業唯一入選藥廠 《Fortune雜誌》3度入圍百大最佳職場 《DOW Jones Sustainability Index, DJSI道瓊企業永續指數》連續17年入選 《Harvard Business Review哈佛商業評論》連續2年評選為全球最佳CEO 第1名 《Pharmaceutical Executive雜誌》 評選為全球製藥業第1名

  • 聯絡人

    :MAPA Team
  • 聯絡電話

推薦給你

此公司職缺